Glial and myeloid heterogeneity in the brain tumour microenvironment.
Brian M AndersenCamilo Faust AklMichael A WheelerE Antonio ChioccaDavid A ReardonFrancisco J QuintanaPublished in: Nature reviews. Cancer (2021)
Brain cancers carry bleak prognoses, with therapeutic advances helping only a minority of patients over the past decade. The brain tumour microenvironment (TME) is highly immunosuppressive and differs from that of other malignancies as a result of the glial, neural and immune cell populations that constitute it. Until recently, the study of the brain TME was limited by the lack of methods to de-convolute this complex system at the single-cell level. However, novel technical approaches have begun to reveal the immunosuppressive and tumour-promoting properties of distinct glial and myeloid cell populations in the TME, identifying new therapeutic opportunities. Here, we discuss the immune modulatory functions of microglia, monocyte-derived macrophages and astrocytes in brain metastases and glioma, highlighting their disease-associated heterogeneity and drawing from the insights gained by studying these malignancies and other neurological disorders. Lastly, we consider potential approaches for the therapeutic modulation of the brain TME.
Keyphrases
- single cell
- resting state
- white matter
- functional connectivity
- dendritic cells
- cerebral ischemia
- neuropathic pain
- stem cells
- rna seq
- end stage renal disease
- small cell lung cancer
- brain metastases
- multiple sclerosis
- bone marrow
- chronic kidney disease
- newly diagnosed
- spinal cord
- endothelial cells
- spinal cord injury
- inflammatory response
- gene expression
- cell therapy
- immune response
- blood brain barrier
- climate change
- subarachnoid hemorrhage